Acrysof Cachet® angle-supported phakic intraocular lens for the correction of moderate to high myopia

Poster Details

First Author: W.Kolodziejczyk POLAND

Co Author(s):    J. Szaflik   J. Szaflik           

Abstract Details

Purpose:

The angle-supported foldable phakic intraocular lens (PIOL) (Acrysof Cachet®, Alcon Inc.) is a relatively new implant for the correction of moderate to high myopia. We report a consecutive case series of 27 eyes with Cachet® PIOL with regard to functional outcome, predictability and patient satisfaction.

Setting:

Department of Ophthalmology, University Medical Center, Johannes-Gutenberg-University, Mainz, Germany

Methods:

Inclusion criteria were myopia between -5 and -16.5 diopters (D) without concomitant eye disease. All patients received Cachet® PIOL implants in both eyes. Outcome measures included pre- and postOP uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), UCVA two hours after implantation, intraocular pressure (IOP) 1 day and 6 months after implantation, endothelial cell density (ECD) and patient satisfaction. IOL power was calculated using a modified van der Heijde formula. Follow-up time was 3-6 months. All patients answered a questionnaire for subjective evaluation.

Results:

27 eyes of 14 patients (12 female, mean age 35 years) were included in this consecutive case series. Preoperative UCVA was <20/200 in all eyes, mean BCVA was 20/25. Mean manifest refraction was -9.5 D (range from -5,5D to -15,5D). Mean UCVA 2 hours postOP was 20/25, 1 and 6 months post OP also 20/25. BCVA at 6 months was 20/20. Mean IOP in the early postoperative period (<1 week) was 16mmHg, at 6 months 15mmHg. Mean preOP endothelial cell density was 2765/mm². Patients had a high degree of satisfaction with the implant (mean 4.7 on a scale 0-5). No adverse reactions were observed.

Conclusions:

Within the follow-up Cachet® PIOL are safe and effective for the surgical correction of myopia and yield predictable results. Patients experienced an immediate visual rehabilitation and are highly satisfied with the implant. Extended follow-up is necessary to address potential concerns about safety and stability. FINANCIAL DISCLOSURE?: No